Search results
Showing 16 to 30 of 2172 results for technology appraisal
In development Reference number: GID-MT526 Expected publication date: TBC
This guideline covers detecting, diagnosing and treating women (aged 18 and older) who have, or are suspected of having, epithelial ovarian cancer, fallopian tube cancer, primary peritoneal cancer or borderline ovarian cancer. It aims to enable earlier detection of ovarian cancer and improve initial treatment.
We are listening to your views on this Technology appraisal guidance. Comments close 8 January 2026.
This guideline covers the diagnosing and managing of myeloma (including smouldering myeloma and primary plasma cell leukaemia) in people aged 16 and over. It aims to improve care for people with myeloma by promoting the most effective tests and treatments for myeloma and its complications.
We are listening to your views on this Technology appraisal guidance. Comments close 18 December 2025.
Our methods and processes (health technology evaluation manual)
NICE's technology appraisal and highly specialised technologies guidance manual
We are listening to your views on this Technology appraisal guidance. Comments close 15 January 2026.
Lifileucel for previously treated unresectable or metastatic melanoma ID3863: draft guidance
We are listening to your views on this Technology appraisal guidance. Comments close 22 January 2026.
In development Reference number: GID-TA11495 Expected publication date: 07 January 2026
Peripheral arterial disease: diagnosis and management (CG147)
This guideline covers diagnosing and managing peripheral arterial disease (PAD) in people aged 18 and over. Rapid changes in diagnostic methods, endovascular treatments and vascular services associated with new specialties in surgery and interventional radiology have resulted in considerable uncertainty and variation in practice. This guideline aims to resolve that uncertainty and variation.
This guideline covers diagnosing and managing non-Hodgkin's lymphoma in people aged 16 years and over. It aims to improve care for people with non-Hodgkin's lymphoma by promoting the best tests for diagnosis and staging and the most effective treatments for 6 of the subtypes. Tests and treatments covered include excision biopsy, radiotherapy, immunochemotherapy and stem cell transplantation.
This guideline covers diagnosing and managing bladder cancer in people 18 and above referred from primary care with suspected bladder cancer, and those with newly diagnosed or recurrent bladder (urothelial carcinoma, adenocarcinoma, squamous-cell carcinoma or small-cell carcinoma) or urethral cancer.
We are listening to your views on this Technology appraisal guidance. Comments close 9 January 2026.
Pharmalgen for the treatment of bee and wasp venom allergy: review proposal consultation
We are listening to your views on this Technology appraisal guidance. Comments close 9 January 2026.
This guideline covers assessing and managing psoriasis in adults, young people and children. It aims to improve long-term disease control and quality of life for people with psoriasis.